pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk is a pharma organization headquartered in bagsværd, DK. Primary therapeutic focus areas include Diabetes, Congenital Bleeding Disorder, Acquired Bleeding Disorder, Overweight, Cardiorespiratory arrest at bir
Novo Alle, Bagsværd, 2880, DK HQ
1923 Founded
63,033 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 34
- Patents
- 0
Ziltivekimab
Phase 3 · small molecule · Heart Failure
Ziltivekimab for Heart Failure is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Internal code EX6018-4915
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Heart Failure
- Status
- active
- Trials
- 1